Roxana Mehran教授

　　這是我第8次參加CIT。對我來說CIT已經成為不容錯過的會議,一是因為其精彩的學術內容,二是因為每年同道們都相聚在此共議學術。我們知道,中國介入心髒病領域飛速發展,人們辛勤工作,開展具備高質量數據的試驗。許多中國原創研究正在影響世界,例如China PEACE研究和BRIGHT研究。

　　CIT可謂中國乃至亞太地區最好的會議,其參會人數量龐大、重視年輕一代的培養、且展示了很多在患者診療方麵的巨大進展。我相信CIT會吸引越來越多的國際關注——如果你錯過了CIT,就意味著錯過太多。會議組織者非常重視有關臨床研究的教育和基礎建設。我期待今年的CIT繼續其重視教育的傳統,促進中國和全球的學術發展。

　　此外,我對有關生物可吸收支架(BRS)和經導管主動脈置換術(TAVR)的報告也非常感興趣。

　　This is my 8th time attending CIT. It is absolutely a must for me to come to this meeting, because of its incredible scientific content, as well as the fact that my colleagues are gathering here every year. We know that China is highly progressive in interventional cardiology. People are working hard, doing excellent trials with data of good quality. There are so many studies of international influence from China now, such as the China PEACE study and the BRIGHT study.

　　CIT is the top meeting in China, or even in the Asia Pacific area, if not the world, because of its tremendous number of attendees, great interest in educating the younger generation and demonstration of huge improvements inpatient care. I am sure that it will attract more and more international attention, as when you miss the CIT, you missed a lot.

　　The organizers are concerned about including enough teaching and infrastructure about clinical research in this meeting. I am expecting this years’ CIT to continue the tradition of education and to promote research both in China and around the world. Except these, I am particularly interested in hearing from China about BRS and TAVR.